# HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

> **NCT02536469** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HuMax-IL8

## Key facts

- **NCT ID:** NCT02536469
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536469, "HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02536469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*